Alopecia areata following COVID-19 vaccine: a systematic review

This systematic review analyzed 25 articles involving 51 patients to examine the occurrence of alopecia areata (AA) following COVID-19 vaccination. It found that 52.9% of patients developed new-onset AA, while 47.1% experienced a recurrence or exacerbation of preexisting AA, with the Pfizer vaccine being most frequently associated. AA typically manifested within one month after the first vaccine dose. Treatments included corticosteroids and Janus Kinase inhibitors, though some patients experienced exacerbations. The study concludes that AA following vaccination is rare, but awareness is crucial for early diagnosis and treatment, especially in patients with a history of AA or thyroid dysfunction.